Lisinopril – jeden z najwszechstronniej zbadanych inhibitorów enzymu konwertującego angiotensynę Artykuł przeglądowy

##plugins.themes.bootstrap3.article.main##

Piotr Jędrusik

Abstrakt

Lisinopril jest jednym z najwszechstronniej zbadanych leków z grupy inhibitorów enzymu konwertującego angiotensynę. W badaniach klinicznych wykazano jego skuteczność w leczeniu nadciśnienia tętniczego, zawału mięśniasercowego, niewydolności serca oraz nefropatii i retinopatii w przebiegu nadciśnienia i/lub cukrzycy, na podstawieuzyskanych dowodów redukcji chorobowości i umieralności z przyczyn sercowo-naczyniowych oraz umieralnościogólnej w obrębie szerokiego spektrum ryzyka sercowo-naczyniowego, od nadciśnienia tętniczego do przewlekłejniewydolności serca. Połączenia lisinoprilu z hydrochlorotiazydem oraz lisinoprilu z amlodypiną, dostępne w postacipreparatów złożonych, mają wszystkie zalety, jakimi powinna się cechować kombinacja leków hipotensyjnychi mogą odgrywać ważną rolę w skojarzonym leczeniu hipotensyjnym, które jest konieczne do osiągnięcia odpowiedniejkontroli ciśnienia tętniczego u większości pacjentów z nadciśnieniem.

Pobrania

Dane pobrania nie są jeszcze dostepne

##plugins.themes.bootstrap3.article.details##

Jak cytować
Jędrusik , P. (2015). Lisinopril – jeden z najwszechstronniej zbadanych inhibitorów enzymu konwertującego angiotensynę. Kardiologia W Praktyce, 9(2), 38-45. Pobrano z https://www.journalsmededu.pl/index.php/kwp/article/view/1346
Dział
Artykuły

Bibliografia

1. Simpson K., Jarvis B.: Lisinopril: a review of its use in congestive heart failure. Drugs 2000; 59: 1149-1167.
2. Lisiprol – charakterystyka produktu leczniczego. Gedeon Richter Polska 2010.
3. Opie L.H.: Inhibitory konwertazy angiotensyny: postęp trwa. Via Medica, Gdańsk 2000.
4. Zannad F., Matzinger A., Larche J.: Trough/peak ratios of once daily angiotensin converting enzyme inhibitors and calcium antagonists. Am. J. Hypertens. 1996; 9: 633-643.
5. Neutel J.M.: Effect of the renin-angiotensin system on the vessel wall: using ACE inhibition to improve endothelial function. J. Hum. Hypertens. 2004; 18: 599-606.
6. Song J.C., White C.M.: Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin. Pharmacokinet. 2002; 41: 207-224.
7. Meredith P.A., Elliott H.L.: Concentration-effect relationships and implications for trough-to-peak ratio. Am. J. Hypertens. 1996; 9: 66S-70S.
8. Martell N., Gill B., Marin R. et al.: Trough to peak ratio of once-daily lisinopril and twice-daily captopril in patients with essential hypertension. J. Hum. Hypertens. 1998; 12: 69-72.
9. Omboni S., Fogari R., Palatini P. et al.: Reproducibility and clinical value of the trough-to-peak ratio of the antihypertensive effect: evidence from the SAMPLE Study. Hypertension 1998; 32: 424-429.
10. Zannad F.: Trandolapril. How does it differ from other angiotensin converting enzyme inhibitors? Drugs 1993; 46(supl. 2): 172-181.
11. Lancaster S.G., Todd P.A.: Lisinopril: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 1988; 35: 646-669.
12. Langtry H.D., Markham A.: Lisinopril: a review of its pharmacology and clinical efficacy in elderly patients. Drugs Aging 1997; 10: 131-166.
13. Hansson L., Lindholm L.H., Ekbom T. et al.: Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354: 1751-1756.
14. Goa K.L., Haria M., Wilde M.I.: Lisinopril: a review of its pharmacology and use in the management of complications of diabetes mellitus. Drugs 1997; 53: 1081-1105.
15. Reisin E., Weir M.R., Falkner B. et al.: Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in Obese Patients With Hypertension (TROPHY) Study Group. Hypertension 1997; 30: 140-145.
16. Solfrizzi V., Scafato E., Frisardi V. et al.: Angiotensin-converting enzyme inhibitors and incidence of mild cognitive impairment. The Italian Longitudinal Study on Aging. Age 2013; 35: 441-453.
17. Fogari R., Mugellini A., Zoppi A. et al.: Effect of telmisartan/hydrochlorothiazide vs lisinopril/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients. J. Hum. Hypertens. 2006; 20: 177-185.
18. Gore P.N., Badar V.A., Hardas M.M. et al.: Comparative effects of telmisartan and lisinopril on cognitive function in metabolic syndrome patients. Int. J. Clin. Exp. Physiol. 2014; 1: 216-220.
19. Hajjar I., Hart M., Chen Y.L. et al.: Effect of Antihypertensive Therapy on Cognitive Function in Early Executive Cognitive Impairment: A Double-blind Randomized Clinical Trial. Arch. Intern. Med. 2012; 172: 442-444.
20. Agabiti-Rosei E., Muiesan M.L.: Left ventricular hypertrophy: how to influence an important risk factor in hypertension. J. Hypertens. 1998; 16(supl.): S53-S58.
21. Goa K.L., Balfour J.A., Zuanetti G.: Lisinopril: a review of its pharmacology and clinical efficacy in the early management of acute myocardial infarction. Drugs 1996; 52: 564-588.
22. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI-3). Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after myocardial infarction. Lancet 1994; 343: 1115-1122.
23. Packer M., Poole-Wilson P.A., Armstrong P.W. et al.: Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999; 100: 2312-2318.
24. Agardh C.D., Garcia-Puig J., Charbonnel B. et al.: Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine. J. Hum. Hypertens. 1996; 10: 185-192.
25. The EUCLID study group: Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997; 349: 1787-1792.
26. Chaturvedi N., Sjolie A.K., Stephenson J.M. et al.: Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet 1998; 351: 28-31.
27. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
28. Cushman W.C., Davis B.R., Pressel S.L. et al.: Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. J. Clin. Hypertens. (Greenwich) 2012; 14: 20-31.
29. Piller L.B., Baraniuk S., Simpson L.M. et al.: Long-term follow-up of participants with heart failure in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Circulation 2011; 124: 1811-1818.
30. Cushman W.C., Ford C.E., Einhorn P.T. et al.: Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J. Clin. Hypertens. (Greenwich) 2008; 10: 751-760.
31. Potter J.F., Robinson T.G., Ford G.A. et al.: Controlling hypertension and hypotension immediately post-stroke (CHHIPS): a randomised, placebo-controlled, double-blind pilot trial. Lancet Neurol. 2009; 8: 48-56.
32. Shaw L., Price C., McLure S. et al.: Paramedic Initiated Lisinopril For Acute Stroke Treatment (PIL-FAST): results from the pilot randomised controlled trial. Emerg. Med. J. 2014; 31: 994-999.
33. Schrader H., Stovner L.J., Helde G. et al.: Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. BMJ 2001; 322: 19-22.
34. Schuh-Hofer S., Flach U., Meisel A. et al.: Efficacy of lisinopril in migraine prophylaxis – an open label study. Eur. J. Neurol. 2007; 14: 701-703.
35. Paterna S., Di Pasquale P., D’Angelo A. et al.: Angiotensin-converting enzyme gene deletion polymorphism determines an increase in frequency of migraine attacks in patients suffering from migraine without aura. European Neurology 2000; 43: 133-136.
36. Wald D.S., Wald N.J.: Implementation of a simple age-based strategy in the prevention of cardiovascular disease: the Polypill approach. J. Eval. Clin. Pract. 2012; 18: 612-615.
37. PILL Collaborative Group. An international randomised placebo-controlled trial of a four-component combination pill (‘‘Polypill’’) in people with raised cardiovascular risk. PLoS ONE 2011; 6: e19857.
38. Soliman E.Z., Mendis S., Dissanayake W.P. et al.: A Polypill for primary prevention of cardiovascular disease: A feasibility study of the World Health Organization. Trials 2011; 12: 3.
39. The Indian Polycap Study (TIPS): Effects of a Polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomized trial. Lancet 2009, 373: 1341-1351.
40. Feldman R.D., Zou G.Y., Vandervoort M.K. et al.: A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension 2009; 53: 646-653.
41. Dahlof B., Sever P.S., Poulter N.R. et al.: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906.
42. Jamerson K., Weber M.A., Bakris G.L. et al.: Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 2008; 359: 2417-2428.
43. Mancia G., Fagard R., Narkiewicz K. et al.: 2013 ESH/ESC Guidelines for the management of arterial hypertension. Eur. Heart J. 2013; 34: 2159-2219.